Bevenopran
Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally selective μ- and δ-opioid receptor antagonist that was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation. It reached phase III clinical trials for this indication before being discontinued.
primaryTopic
Bevenopran
Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally selective μ- and δ-opioid receptor antagonist that was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation. It reached phase III clinical trials for this indication before being discontinued.
has abstract
Bevenopran (INN, USAN) (former ...... ion before being discontinued.
@en
CAS number
676500-67-7
IUPAC name
5-[2-Methoxy-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyrazine-2-carboxamide
@en
PubChem
thumbnail
Wikipage page ID
48.830.695
Wikipage revision ID
744.749.846
ChemSpiderID
legal status
Investigational
molecular weight
3,8644484e+2
smiles
COC1=COC3=NC=CCN
StdInChIKey
ZGCYVRNZWGUXNQ-UHFFFAOYSA-N
subject
comment
Bevenopran (INN, USAN) (former ...... ion before being discontinued.
@en
label
Bevenopran
@en
